An interventional study of TIVUS™ Renal Denervation System and Sham in Hypertension, sponsored by SoniVie Inc.. Recruiting at 51 sites in 5 countries. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by SoniVie Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,032 studies in Hypertension with a site in United States — 268 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,032 studies in Hypertension with a site in United States, this one is the 544th largest by planned enrollment of the 1,780 interventional ones that give a count, is one of 93 that started in 2024, is one of 1,072 with no phase, reaches primary completion later than 127 of the 367 other live ones, and was the 1,813th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →268 of the 2,032 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 22 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,032 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 93 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 261 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,780 interventional studies, 200 across the 238 observational. Of the 1,515 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,032 have an industry lead sponsor. The 10 most frequent:
SoniVie Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
SoniVie Inc. has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
144 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 144 to your calendar (.ics) → With an account.
Among the 2,032 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the THRIVE Pivotal study is to demonstrate the adjunctive effectiveness and the safety of the TIVUS system in:
THRIVE is an international, multicenter, randomized, double blind, sham-controlled study, designed to demonstrate the adjunctive effectiveness and safety of the TIVUS System in hypertensive subjects while subjects are maintained off-antihypertensive medications for a 4-week wash-out period before RDN/Sham procedure and 2 months after procedure. At two months after procedure, subjects with uncontrolled hypertension are put back on antihypertensive medication according to a medication escalation protocol. Unblinding will be performed at 6 months. Uncontrolled sham subjects can cross-over to RDN procedure at 6-months. The sham procedure will be minimally invasive to reduce risk to subjects. All subjects treated with TIVUS will be followed for a maximum of 36 months post procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has an office BP (average of 3 seated measurements) of:
Subjects who meet the following criteria will be considered eligible for randomization:
Suitable renal anatomy compatible with the renal denervation procedure, documented by renal CTA or MRA of good quality performed within one year prior to consent (a CTA or MRA will be obtained in subjects without a recent (≤1 year) cross-sectional renal imaging). The renal angiogram procedure done in the cath lab prior to randomization will serve as the final anatomy compatibility check.
Exclusion Criteria:
Pregnant, nursing or planning to become pregnant within 12 months post procedure.
Negative pregnancy test required, documented within a maximum of 7 days prior to procedure for all women of . Documentation of effective is also required for women of childbearing potential
Angiographic Exclusion Criteria:
The following characteristics identified either on the renal artery CT scan or MRI or on the Eligibility II Renal artery Angiogram will prevent the subject from being included:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following angiogram, subjects found anatomically eligible and randomized to the renal denervation arm will be treated with the TIVUS™ Renal Denervation System.
Device: TIVUS™ Renal Denervation System
For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
Other: Sham
Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.
Also known as: Renal Denervation
For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
Reduction in average daytime ambulatory systolic BP
Primary outcome
Time frame: From baseline to 2 months post-procedure
Subject level composite of the incidence of Major Adverse Events (MAE)
Safety outcome
Time frame: From Baseline to 30 day and 6 months post procedure
Reduction in average 24-hr ambulatory systolic BP
Secondary outcome
Time frame: From baseline to 2 Months post procedure
Reduction in average home systolic BP
Secondary outcome
Time frame: From baseline to 2 Months post procedure
Reduction in average office systolic BP
Secondary outcome
Time frame: From baseline to 2 Months post procedure
Reduction in average daytime ambulatory diastolic BP
Secondary outcome
Time frame: From baseline to 2 Months post procedure
Reduction in average 24-hr ambulatory diastolic BP
Secondary outcome
Time frame: From baseline to 2 Months post procedure
Reduction in average home diastolic BP
Secondary outcome
Time frame: From baseline to 2 Months post procedure
Reduction in average office diastolic BP
Secondary outcome
Time frame: From baseline to 2 Months post procedure
Percentage of subjects with Systolic Blood Pressure (SBP) at target (daytime SBP <135 mmHg; office SBP <140
Secondary outcome
Time frame: From baseline to 2 and 6 Months post procedure
Percentage of subjects with SBP at target (daytime SBP <135 mmHg; office SBP <140 mmHg) in the absence of. changes in hypertensive medication in each arm
Secondary outcome
Time frame: From baseline to 2 and 6 Months post procedure
Incidence of ambulatory systolic BP (daytime/24-hr/night-time) reductions of ≥5 mmHg, ≥10 mmHg, and ≥15 mm Hg
Secondary outcome
Time frame: From baseline to 2, 6, and 12 Months post procedure
Reduction in average night-time ambulatory systolic/diastolic BP
Observational outcome
Time frame: From baseline to 2, 6 and 12, Months post procedure
Reduction in average daytime & 24-hr ambulatory systolic BP at 6- and 12-months post procedure.
Observational outcome
Time frame: From baseline to 6 and 12 Months post procedure
Reduction in average daytime & 24-hr ambulatory diastolic BP
Observational outcome
Time frame: From baseline to 6 and 12 Months post procedure
Reduction in average office systolic BP
Observational outcome
Time frame: From baseline to 6 and 12 Months post procedure
Reduction in average home systolic/diastolic BP
Observational outcome
Time frame: From baseline to 1, 3, 4, 5, 6, and 12-Months post procedure
Reduction in office and ambulatory pulse pressure
Observational outcome
Time frame: From baseline to 2, 6 and 12 Months post procedure
Reduction in office and ambulatory heart rate
Observational outcome
Time frame: From baseline to 2, 6, and 12 Months post procedure
Antihypertensive medication burden (number of antihypertensive drugs, doses, classes)
Observational outcome
Time frame: From baseline to 2, 6 and 12 Months post procedure
Percentage of subjects meeting escape criteria
Observational outcome
Time frame: From baseline to 2 Months post procedure
Percentage of subjects requiring initiation of antihypertensive drug therapy
Observational outcome
Time frame: From baseline to 2 and 6 Months post procedure
Percentage of subjects without any antihypertensive treatment
Observational outcome
Time frame: From baseline to 6 and 12 Months post procedure
Percentage of subjects requiring initiation of anti-hypertensive drug therapy at any available time points post procedure
Observational outcome
Time frame: From baseline through completion of study
Change in adherence to medications assessed by urine chemical adherence testing using liquid chromatography with tandem mass spectrometry (LCMSMS)
Observational outcome
Time frame: From baseline to 2, 6, 12, 24 and 36 Months.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.
Of 95 industry-sponsored interventional studies with no phase under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 29 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SoniVie Inc.